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Binding of serum immunoglobulins to collagens in IgA nephropathy
and HIV infection. The mechanism of the binding of IgA to the
mesangium in IgA nephropathy (IgAN) is unknown. Interactions be-
tween IgA and components of the mesangial matrix may contribute. We
measured by enzyme-linked immunosorbent assay the binding of serum
IgA, IgG, and 1gM from patients with IgAN, human immunodeficiency
virus type I (HIV) infection, and healthy controls to purified native
collagen types Ito VI, and to an extract of normal kidney tissue. HIV
infection is an appropriate disease control because of the lack of
mesangial IgA deposits, despite high serum levels of IgA and IgAl-
containing immune complexes. Increased levels of IgA-binding to
collagen types I and V and the kidney extract were found only in IgAN.
Both IgAN and HIV-infected patients had increased IgA-binding to
collagen types II, III, and VI. Preabsorption of the sera with gelatin
substantially reduced the IgA-binding to collagen types Ito IV, but not
to types V and VI. This finding suggests that the binding to collagen
type V is not fibronectin-mediated, but may reflect autoantibody
formation. Thus, fibronectin-mediated IgA-collagen interactions are not
specific for IgAN, and their pathogenetic role is questionable. The role
of IgA anti-collagen type V antibodies requires further study.
Primary IgA nephropathy (IgAN) is a common form of
glomerulonephritis with a varied spectrum of clinical presenta-
tions, leading to a slowly progressive renal failure in a substan-
tial proportion of patients [1]. The disease is characterized by
deposits of IgAl, derived from the blood stream, in the glomer-
ular mesangium [2, 3]. Although increased plasma levels of
IgAl and IgAl-containing immune complexes are thought to be
of pathogenetic importance, the mechanism of the mesangial
deposition remains unclear [3—11]. Certainly, elevated plasma
levels of IgAl or IgA 1-containing immune complexes alone are
not sufficient to cause mesangial deposition of IgAl, as wit-
nessed by the rare occurrence of IgAN in patients with IgA 1
myeloma or infection with the human immunodeficiency virus
type I (HIV) [12, 13]. Despite the numerous renal biopsy or
autopsy specimens examined from HIV-infected patients,
mesangial deposits of IgA have only rarely been found [14—19].
Recently, several reports have suggested that the binding of
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immunoglobulins to the mesangium in IgAN may be mediated
through either a fibronectin-collagen interaction, or through
autoantibodies directed at glomerular components [20—22]. If
such mechanisms are indeed of pathogenetic relevance in
IgAN, these interactions should differ between patients with
IgAN and HI V-infected individuals, as the latter patients usu-
ally lack mesangial IgAl deposits. Thus, in this study, we have
compared the binding of serum immunoglobulins from IgAN
patients, HIV-positive patients, and healthy controls to various
preparations of extracellular matrix (ECM) components.
Methods
Patients and controls
Sera were obtained from 26 White patients (18 males, 8
females) with biopsy-proven primary IgAN. Ages ranged from
14 to 62 years (mean 36 years). Renal function, as assessed by
the serum creatinine concentration, was normal (creatinine 1.2
mg/100 ml or less) in 18 patients. Eight patients had mild to
moderate impairment of renal function with serum creatinine
concentrations between 1.2 and 3.1 mg/100 ml. Twenty-seven
patients with serologically-established HIV infection (19 males,
8 females) constituted the second group. Ages ranged from 19 to
47 years (mean 36 years). Twenty-one patients were White and
six were Black. The clinical staging of these patients according
to the CDC criteria [23] was as follows: five were stage II, two
were stage III, one was stage IVb, 12 were stage IVcl, and
seven were stage IVc2. Twenty-six healthy White laboratory
employees (19 males, 7 females) served as the normal control
group. Ages ranged from 23 to 56 years (mean 30 years). Only
the White HIV-infected patients were included in the final
comparison of the three patient groups, because race proved to
be an independent determinant in the results for many of the
variables studied.
To inactivate HIV in the serum samples, Nonidet NP4O
(Sigma Chemical Company, St. Louis, Missouri, USA) was
added to a final concentration of 0.1%. To insure comparability
between the groups, the sera in the IgAN and control groups
were similarly treated. The sera were stored at —20°C until the
time of the study. The total serum concentrations of IgG, IgA,
and 1gM were measured by rate nephelometry using commer-
cial standards.
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Extracellular matrix preparations
Native collagen types I to VI were isolated from human
tissues by partial proteolysis and sequential salt precipitation,
and characterized by published methods [24]. Collagen types I
and III were isolated from amnion. Collagen type IV was
isolated from chorion, and types V and VI were isolated from
whole placenta. Collagen type II was isolated from a human
chondrosarcoma. Stock solutions were maintained in 0.5 M
aceticacid at 4°C. A kidney extract was prepared from the renal
cortex of the unaffected portion of a nephrectomy specimen
from an 8-month-old White female with a Wilms' tumor. The
tissue was stored at —70°C until use. Approximately 400 mg of
tissue was minced with a scalpel blade and washed twice in cold
phosphate buffered saline (PBS) to remove serum proteins. The
tissue fragments were resuspended in 1 ml Tris-HC1 buffer (pH
8.0) containing 1% sodium dodecyl sulfate and 5% f3-mercapto-
ethanol. After homogenization in a glass tissue grinder, the
mixture was boiled for five minutes and cooled on ice. Remain-
ing particulate matter was removed by centrifugation, and the
supernatant aliquoted and stored at —20°C. The total protein
content was measured according to Lowry's method. The
extract contained negligible quantities of immunoglobulins, as
determined by enzyme-linked immunosorbent assay (ELISA).
Enzyme-linked immunosorbent assay
Polystyrene microtiter plates (Linbro/Titertek, Flow Labora-
tories, McLean, Virginia, USA) were coated overnight at room
temperature with 100 p1/well of the individual matrix prepara-
tions at a concentration of 10 gIml in borate buffered saline
(pH 8.5) [25]. After washing with PBS (pH 7.2), the wells were
blocked for four hours at 37°C and overnight at 4°C with 200
p1/well of PBS containing 0.15% Tween 20 (Sigma) and 1%
bovine serum albumin (BSA) (Sigma) (PBS-Tween-BSA). This
buffer was also used as a diluent in all subsequent steps of the
ELISA. Between each of the following steps in the ELISA, the
plates were washed six times with PBS containing 0.15% Tween
20 in an automated plate washer (Dynatech Laboratories, Inc.,
Chantilly, Virginia, USA). The sera were diluted 1:100 (or
higher if high levels of immunoglobulin binding were detected),
and assayed in duplicate wells at 100 p1/well. After an overnight
incubation at 4°C, bound immunoglobulins were detected with
affinity-purified, biotin-labelled goat F(ab)2 fragments specific
for the heavy chains of human IgG, IgA, or 1gM (Tago Inc.,
Burlingame, California, USA). The incubation with the bioti-
nylated antibodies was performed at 37°C for two hours, and
followed by avidin-conjugated peroxidase (Sigma) for one hour
at 37°C. Conversion of the substrate [2,2'-azino-bis (3- ethyl-
benzthiazoline-6-sulfonic acid) (Sigma), containing 0.0075%
H202)] was measured at 414 nm on an Anthos 2001 plate reader
(Anthos Labtec Instruments, Salzburg, Austria). For each type
of ELISA, characterized by matrix preparation and isotype, a
serum with a high degree of binding was selected as a standard
and assigned a titer of 3200 arbitrary U/ml. This standard serum
was included in duplicate on each plate in seven twofold
dilution steps, to construct a standard curve. OD readings of
blanks, obtained in wells containing no serum, were subtracted
from the OD values in the wells containing standards and
unknowns. The titers in the test sera were obtained by interpo-
lation on the standard curves using a four-parameter modelling
procedure (Deltasoft, BioMetallics Inc., Princeton, New Jer-
sey, USA). Sera with titers less than 25 U/ml (the lower
detection limit) were arbitrarily assigned a titer of 25 U/ml for
the statistical analysis. In preliminary experiments, all sera
were also measured in wells which had been treated only with
the blocking solution, and the binding of IgG, IgA, and 1gM was
negligible.
Inhibition ELISA
The specificity of the ELISA used in this study was further
tested by inhibiting the binding of IgA to the solid phase after a
preincubation of sera, selected for a high level of IgA binding,
with the homologous type of collagen. The sera were diluted
1:100 in PBS-Tween-BSA containing increasing concentrations
of the inhibitor collagen. After incubation overnight at 4°C, the
samples were assayed in the ELISA described above. In
addition, heterologous inhibition was examined: the binding to
collagen types II to VI was inhibited by increasing concentra-
tions of collagen type I. Similarly, the binding to collagen type
I was inhibited by increasing concentrations of collagen type V.
In all inhibition studies, the remaining IgA binding to the solid
phase after inhibition was expressed as a percentage of the OD
value in the original serum.
Absorption to gelatin and anti-fl bronectin
To investigate the mechanism of the binding of IgA to the
collagens and the possible role of fibronectin-IgA aggregates,
we performed affinity-absorption experiments on 16 sera (8
IgAN and 8 HIV) selected for the highest level of IgA-binding to
collagen type V. The sera were first absorbed to gelatin (Sigma)
coupled to Sepharose CL-4B beads (Pharmacia Fine Chemi-
cals, Piscataway, New Jersey, USA) (approximately 5 mg
gelatin/ml gel) to allow fibronectin-IgA aggregates to bind to the
fibronectin-binding sites on denatured collagen type I [21, 26,
27]. As a control, the sera were absorbed in parallel to BSA
coupled to Sepharose CL-4B beads. All absorptions were
performed in microcentrifuge tubes by overnight rotation at
4°C, followed by centrifugation and harvesting of the superna-
tants. A ratio of packed immunoabsorbent to serum of approx-
imately 1:4 was used, as this has previously been shown to
remove more than 80% of the total fibronectin from serum
samples (L.M. Switalski and M. Hook, unpublished observa-
tions). After the first absorption to gelatin, a second absorption
to monospecific, polyvalent rabbit anti-fibronectin IgG coupled
to Sepharose CL-4B beads (approximately 2 mg IgG/ml gel) was
performed in a similar fashion, to achieve more complete
removal of all fibronectin-containing material from the sera.
The second absorption was performed on an aliquot of the
supernatant after the gelatin absorption, with a second aliquot
being absorbed to the control immunoabsorbent BSA. In this
fashion, a total of five samples, including the pre-absorption
serum sample, were obtained from each of the 16 sera. These 80
samples were assayed in the various ELISA's measuring the
binding of IgA to matrix components, and the results expressed
in units as described above. The level of binding after the
various absorption steps was expressed as a percentage of the
preabsorption titer.
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Immunofluorescence Results
To further investigate the binding of IgA to mesangial matrix,
we selected 13 sera with the highest level of IgA binding to
collagen type V (8 IgAN and 5 HIV sera). Frozen sections from
the kidney specimen used for the preparation of the kidney
extract were fixed in 96% ethanol containing 5% glacial acetic
acid for 20 minutes at —20°C. After washing with PBS, the
sections were overlayed with a 1:10 dilution of the sera in PBS
containing 1% BSA. As a negative control, we used a 1:10
dilution of pooled normal human serum. Following the 30
minute incubation, the sections were washed and stained with a
goat F(ab)2 anti-human IgA antibody coupled to fluorescein
isothiocyanate (Southern Biotechnology Associates, Inc., Bir-
mingham, Alabama, USA). The intensity of staining for IgA
was judged independently by two observers by fluorescence
microscopy.
Statistical analysis
The U/mI obtained in the various ELISA's indicated that the
probability distributions were not normal, but followed right-
skewed distributions whose standard deviations appeared to be
roughly linear with the means. Transformation of these data to
their common logarithms appeared to yield values whose vari-
ances were more homogeneous from group to group and which
were more nearly normally distributed. Values that were below
the threshold for an assay were set to the lowest detectable
reading (25 U/ml) before being transformed. There were four
groups for comparison: White patients in each of the IgAN,
HIV-infected and control groups, and Black HIV-infected
patients. The comparisons chosen were: comparison among the
three groups of White individuals, and comparison of Black
versus White patients in the HI V-infected group. Racial differ-
ences were often found among the HIV-infected patients,
making it inappropriate to pooi over race in the disease group
comparisons. Consequently, comparisons among the three dis-
ease groups were made only in the White individuals. Signifi-
cance levels for these comparisons were initially determined
using contrasts to define each of the individual comparisons. A
Bonferroni multiple comparisons adjustment was used for the
three paired comparisons among the White individuals. The
basic statistical analysis used was an analysis of covariance for
a two-way classification with unequal subclass number. Gender
and the four groups with their interaction were the fixed effects
of interest, and age was used as a covariate. Results were
expressed as adjusted geometric means with their asymptotic
standard errors. A second analysis was also performed in which
the total serum IgA concentration was an additional covariate.
Correlations among the various parameters were assessed
using principal component analysis of the correlation matrices
for the log-transformed data. These were done with two types
of parameter groupings: with the three different isotypes to-
gether that were measured on the same ECM preparation, and
with the ECM preparations together that were measured for
binding of the same isotype, Tests for differences in relationship
of a pair of parameters among the groups were done by testing
for differences in slope using analysis of covariance methods.
Specificity of the assays
Background binding of immunoglobulins to blocked uncoated
wells was negligible for all sera. Although direct comparisons
between the amounts of immunoglobulin bound to the various
ECM preparations were not possible, the much slower color
development noted in the collagen type IV ELISA for all
isotypes suggested a considerably lower degree of binding than
with the other types of ECM preparation. The binding of IgA to
the collagen types Ito VI was inhibited by increasing amounts
(0.5 to 50 j.g/ml) of the same ligand in a dose-dependent fashion.
For collagen type I the mean percentage of binding remaining
after inhibition with 50 tg/ml of collagen type I was 4% (N = 6).
For collagen type V the mean remaining percentage was 25% (N
= 6). For each of the remaining types of collagen three sera
were studied. The mean remaining binding levels at 50 g/ml of
the inhibitor were: collagen type II 22%; collagen type III 16%;
collagen type IV 47%; collagen type VI 30%. These findings
demonstrate that the binding to the collagens on the solid phase
was specific, although it does not explain the mechanism of the
collagen-immunoglobulin interaction.
In addition, we studied heterologous inhibition. Collagen
type I at 50 g/ml substantially inhibited the binding to collagen
types II to IV: for collagen type lithe mean remaining percent-
age was 27%; for collagen type III 13%; for collagen type IV
21%. In contrast, the inhibition of the IgA binding to collagen
types V and VI by collagen type I at 50 Wml was much less
effective: for collagen type V the mean remaining percentage
was 64%; for collagen type VI 88%. However, when collagen
type V was used as an inhibitor at 50 g/ml in the collagen type
I binding assay, the inhibition was nearly complete, with a mean
remaining percentage of 3%. The inhibition studies for the
collagen types I and V are presented in Figure 1.
Comparison of the patient groups
The main differences in the level of immunoglobulin binding
to the various preparations of ECM components were in the
IgA isotype. IgAN patients had significantly higher binding of
IgA to the collagen types I and V than both healthy controls and
the HIV-inlected patients. The binding to the kidney extract
was highest in the IgAN group, intermediate in the HIV-
infected patients, and lowest in the healthy controls, with
statistically significant differences between all three groups.
The binding of IgA to collagen types II, III, and VI was
significantly elevated in both the IgAN and the HIV patients
when compared with the healthy controls. The level of IgA
binding to collagen types II, III, and VI did not significantly
differ between the IgAN and HIV groups. The results for the 3
isotypes are summarized in Table 1.
The levels of binding to the ECM preparations for IgG and
1gM showed few statistically significant differences between the
patient groups. The IgAN and the HIV patients had diminished
binding of IgG to collagen type VI, and of 1gM to collagen type
IV when compared with the healthy controls. The HI V-positive
patients showed decreased binding of IgG to collagen type II
compared with the IgAN patients and healthy controls.
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Fig. 1. Fluid-phase inhibition ELISA. The
binding of IgA to collagen type I or type V on
the solid phase was inhibited by preincubation
of sera, selected for a high level of binding,
with the homologous and the heterologous
type of collagen. Along the x-axis is the
increasing concentration of the inhibitor (pg/
ml), along the y-axis the percentage of the
original OD remaining after absorption. Open
symbols represent sera from 3 IgAN patients,
closed symbols sera from 3 HIV-infected
patients. A and B show the inhibition of IgA
binding to collagen type I by fluid phase
collagen type 1(A), and fluid phase collagen
type V (B). C and D show the inhibition of
0 0.5 5 50 IgA binding to collagen type V by fluid phase
collagen type V (C), and fluid phase collagen
type 1(D).Inhibitor, 4v.sg/mI
Table 1. Binding of serum immunoglobulins to extracellular matrix preparations
Isotype Matrix type IgAN
White
HIV
Black
HIV Control
Comparison of groups
(limited to Whites) P value
IgA
IgA
IgA
IgA
IgA
IgA
IgA
collagen I
collagen II
collagen III
collagen IV
collagen V
collagen VI
kidney extr.
164 (40)
1007 (238)
600 (133)
580 (213)
779 (126)
561 (107)
1943 (274)
60 (17)
788 (213)
434 (110)
216 (91)
375 (70)
353 (77)
1166 (188)
99 (48)
932 (441)
812 (360)
1694 (1243)
976 (316)
537 (205)
2019 (570)
65 (16)
314 (77)
203 (47)
273 (104)
278 (47)
193 (38)
714 (104)
IgAN > HIV and Control
HIV and IgAN > Control
HIV and IgAN > Control
IgAN > HIV and Control
HIV and IgAN > Control
IgAN > HIV > Control
0.007
0.002
0.003
NS
<0.0001
0.0008
<0.0001
IgG
IgG
IgG
IgG
IgG
IgG
IgG
collagen I
collagen II
collagen III
collagen IV
collagen V
collagen VI
kidney extr.
706 (160)
539 (64)
674 (108)
461 (99)
1975 (368)
324 (27)
575 (43)
347 (90)
372 (51)
430 (79)
348 (85)
1248 (267)
308 (29)
551 (48)
613 (278)
515 (122)
809 (259)
1193 (510)
6688 (2496)
464 (77)
715 (108)
433 (101)
555 (68)
441 (73)
528 (117)
2294 (443)
417 (36)
530 (41)
HIV < Control and IgAN
HIV and IgAN <Control
NS
0.047
NS
NS
NS
0.035
NS
1gM
1gM
1gM
1gM
1gM
1gM
1gM
collagen I
collagen II
collagen III
collagen IV
collagen V
collagen VI
kidney extr.
361 (42)
335 (43)
245 (29)
2720 (491)
894 (1574)
463 (68)
625 (82)
405 (55)
382 (56)
325 (44)
3159 (653)
1130 (228)
463 (78)
896 (134)
251 (59)
256 (66)
193 (45)
2770 (1001)
770 (272)
255 (75)
765 (200)
408 (50)
357 (48)
304 (37)
5620 (1051)
1173 (214)
476 (73)
711 (96)
HIV and IgAN < Control
NS
NS
NS
0.016
NS
NS
NS
Values are geometric means (asymptotic sEM) of the arbitrary units/ml. The means are adjusted for the covariates age and gender. Comparisons
between the three groups of White patients were performed by ANCOVA of the log transformed values.
Total serum immuno globulin concentrations
As shown in Table 2, the IgAN patients had significantly
higher levels of IgA than the healthy control group, while the
HIV-infected patients had significantly elevated levels of IgG,
IgA, and 1gM when compared with both the healthy controls
and the IgAN patients.
Correlations between the various parameters
0 0.5 5 50
to all of the ECM preparations when the data from the three
groups were taken together. Within each of the three groups
these significant positive correlations remained, with two ex-
ceptions: in the healthy control group the binding to collagen
type I was only weakly correlated to total IgA (r = 0.31; P =
0.13), and in the HIV-infected patients the correlation between
binding to collagen type V and total IgA was even weaker (r =
0.11; P = 0.59). In order to mathematically adjust for this effect
A statistically significant positive correlation was found be- of total IgA concentration on the levels of IgA binding, we
tween the total IgA concentration and the level of IgA binding repeated the statistical analysis with the total IgA concentration
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Table 2. Total serum immunoglobulin concentrations
Isotype IgAN
White
HIV
Black
HIV Control
Comparison of groups
(limited to Whites) P value
IgA
IgG
1gM
2.9 (0.3)
10.3 (0.5)
1.4 (0.1)
4.8 (0.6)
18.1 (1.1)
2.1 (0.2)
5.5 (1.2)
28.2 (2.9)
1.5 (0.3)
1.6 (0.2)
11.0 (0.6)
1.5 (0,1)
HIV > IgAN > Control
H!V > IgAN and Control
HIV> IgAN and Control
<0.0001
<0.0001
<0.01
Values are geometric means (asymptotic sEM) of mg/mI. The means are adjusted for the covariates age and gender. Comparisons between the
three groups of White patients were performed by ANCOVA of the log transformed values.
Table 3. Binding of IgA to extracellular matrix preparations, adjusted for total IgA concentration
White Black Comparison of groups
Isotype Matrix type IgAN HIV HIV Control (limited to Whites)
P
value
IgA collagen! 166 (17) 49(7) 55 (11) 101 (13) IgAN > HIV
IgA collagen II 1022 (92) 441 (55) 414 (75) 712 (81) !gAN > H!V
IgA collagen II! 627 (48) 262 (27) 359 (55) 395 (38) !gAN > HIV
IgA collagen !V 602 (88) 135 (27) 589 (174) 646 (120) H!V < IgAN and Control
!gA collagen V 776 (54) 345 (33) 723 (102) 340 (30) !gAN> HIV and Control
IgA collagen VI 579 (46) 287 (32) 338 (55) 277 (28) IgAN > HIV and Control
IgA kidney extr. 1975 (106) 985 (73) 1288 (139) 1015 (69) IgAN > HIV and Control
0.0099
0.0578
0.01 18
0.0283
0.0011
0.0159
0.0004
Values are geometric means (asymptotic saM) of the arbitrary units/mI. The means are adjusted for the covariates total IgA concentr
and gender. Comparisons between the three groups of White patients were performed by ANCOVA of the log transformed values.
ation, age
included as a covariate in the model. As shown in Table 3, the
increased IgA binding to collagen types I to III found in the
unadjusted data was no longer apparent when this correction
for total IgA concentration was made. Nevertheless, the in-
creased binding of IgA to collagen types V and VI and to the
kidney extract remained, and became exclusive for the IgAN
patients.
When the data from all three groups were taken together, the
total 1gM concentrations also showed significant positive cor-
relations to the binding of 1gM to all of the ECM preparations.
The same analysis for IgG revealed weak positive correlations
that were statistically significant only for the collagen types III
to V and for the kidney extract.
The binding of IgA to one ECM preparation in general also
showed a significant positive correlation to the level of binding
to the other ECM preparations. In the healthy controls and the
IgAN patients, the level of IgA binding to a given ECM
preparation was generally positively correlated to the level of
IgG binding to the same preparation. In contrast, the level of
1gM binding generally showed negative or absent correlations
with the levels of IgA and IgG binding to the same ECM
preparation. In the HIV-infected patients, all three isotypes
generally showed positive correlations in their binding to the
same ECM preparation.
Role offibronectin in the collagen-IgA interaction
The results of the affinity-absorption of eight IgAN and eight
HIV-positive sera, selected for high degrees of IgA binding to
collagen type V, are shown in Figure 2. Absorption to gelatin
substantially reduced the amount of IgA binding to the collagen
types Ito IV in both patient groups. By contrast, the amount of
IgA binding to the collagen types V and VI was not significantly
influenced by gelatin absorption. The subsequent incubation of
the gelatin-absorbed sera with anti-fibronectin coated beads did
not further reduce the IgA-binding to any of the collagen types,
suggesting that the removal of IgA-fibronectin aggregates was
complete after the first absorption. For each of the 16 sera the
U/ml after the gelatin absorption was expressed as a percentage
of the U/ml remaining after the control absorption to BSA. This
percentage measures the effect of the removal of fibronectin
from the serum on the binding to collagens. The results for
IgAN and HIV patients are shown in Table 4.
Effects of age, gender and race
The statistical analysis revealed independent effects of age,
gender and race on several of the parameters measured. The
level of 1gM binding to all of the ECM preparations showed a
significant negative correlation with age. Similarly, the total
1gM concentration was negatively correlated with the age of the
individuals. The level of IgA binding to collagen type IV was
positively correlated with age. No age effect was found for the
binding of IgA to the other ECM preparations, the binding of
IgG to ECM preparations, or the total concentrations of IgA
and IgG.
Gender proved to have an independent effect on several of
the parameters measured. Females had significantly higher
concentrations of total 1gM, as well as binding of 1gM to
collagen types I, II, III, V, VI, and kidney extract. Likewise,
the level of IgG binding to kidney extract was higher in females.
However, the binding of IgG to collagen type II was higher in
males.
Within the HIV group we studied the effects of race. Such
comparisons were not possible in the IgAN and control groups
that were comprised of only White individuals. Among the
HIV-infected individuals, significantly higher levels were found
in Blacks for the following parameters: total IgG concentration,
and binding of IgG to collagen types IV, V, and VI. Similarly,
Blacks had significantly higher binding of IgA to collagen types
IV and V.
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Immunofluorescence
Glomerular binding of IgA was found in two of the eight
IgAN sera. The staining was graded as + to + + (on a scale of
0 to + + +), and was seen in a mixed mesangial and capillary
pattern. In addition, one of the two positive sera also showed
nuclear staining throughout the kidney specimen. Of the five
HIV-positive sera, two showed weak glomerular staining for
IgA, and one strong (+ + to + + +) diffuse staining of the entire
tissue. Staining was absent in all remaining sera, and in the
negative control.
Discussion
The mechanism responsible for the mesangial deposition of
IgA in primary IgAN has remained unclear, despite numerous
investigations. Although increased levels of total IgAl and
IgAl-containing immune complexes in the circulation are
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Table 4. Effect of absorption to gelatin-Sepharose on IgA
binding to ECM
ECM
preparation IgAN HIV P value
Collagen type I 56.5 (5.6) 77.0 (5.2) 0.022
Collagen type II 64.2 (6.5) 79.8 (2.5) 0.059
Collagen type III 70.9 (5.8) 83.1 (4.6) 0.133
Collagen type IV 13.9 (4.3) 35.6 (8.1) 0.029
Collagen type V 94.5 (15,2) 80.4 (4.3) 0.355
Collagen type VI 94.8 (4.6) 100.5 (3.8) 0.356
Kidney extract 75.4 (10.0) 95.5 (7.5) 0.146
Remaining ECM-binding IgA expressed as percentage of control
absorption to BSA. Values are geometric means (asymptotic SEM).
Comparisons between the two groups of patients were performed by
two-tailed 1-test on the logarithmically transformed data.
thought to be important in this respect, neither factor ade-
quately explains the mesangial deposition [3—111. This short-
coming is clearly illustrated by the general lack of mesangial
IgA deposits in diseases characterized by elevated total serum
IgAl levels (such as IgAl myeloma), or the combined presence
of increased total IgAl and IgA 1-containing immune complexes
(such as HIV infection) [12—19]. The retention of IgAl in the
mesangium in IgAN is evidently determined by other charac-
teristics. Possible factors include the antigenic specificity of the
IgAl as well as factors unrelated to the specificity. With regard
to the antigenic specificity, either exogenous antigens, such as
alimentary or microbial components, or endogenous antigens
(native to the mesangiuni or non-mesangial) may be implicated.
Factors unrelated to the antigenic specificity of the IgAl may
include physicochemical properties of the circulating IgA 1,
such as size, charge, and glycosylation, or alternatively, bio-
chemical properties of molecules attached to the circulating
IgAl, such as fibronectin [211. In general, the search for
exogenous antigens in the mesangial deposits has been unre-
warding [reviewed in 28]. In the present study, we have sought
to identify characteristics of the circulating IgA enabling it to
bind to components of the mesangial matrix, by comparing the
IgA in sera from IgAN patients to that from sera of healthy
controls, and from sera of HI V-infected patients.
Our studies clearly show increased binding of IgA in IgAN
sera to a crude extract of normal kidney, and to several purified
ECM components (collagen types I, II, III, V, and VI). How-
ever, it is of great importance in the interpretation of these data
to note that such increased binding of IgA to both the kidney
extract and certain collagen types (II, III, and VI) was also
found in the sera from HI V-infected individuals. In view of the
reported low prevalence of mesangial IgA deposits in HIV
infection, this observation implies that the increased binding of
IgA to these types of collagen is not relevant to the mesangial
deposition. The distinction between the IgAN patients and the
HIV patients then centers on the increased binding of IgA to
collagen types I and V, found only in the IgAN sera. This
greater binding of IgA is startling because the total serum IgA
concentration was much higher in the HIV group. This finding
suggests that the increased binding to these two types of
collagen does not merely reflect a polyclonal stimulation result-
ing in increased total serum IgA concentrations.
The selectively increased binding of IgA in IgAN sera to
collagen type V, an important constituent of human mesangial
matrix [29, 30], may be pathogenetically relevant. The binding
of IgA to the crude kidney extract showed significant differ-
ences between the three patient groups, with the highest level in
the IgAN patients. Because IgAN patients manifested signifi-
cantly higher binding to this preparation than the HIV patients,
the kidney extract may also contain one or more components
that are relevant to the mesangial deposition. Future studies
using immunoblotting or immunoprecipitation with IgAN sera
may identify the responsible components in the extract. The
pathogenetic relevance of the increased binding of IgA to
collagen type I, which is not present in normal mesangial matrix
and appears only in fibrosing lesions [29, 30], is not apparent.
The binding of IgA to collagen type IV was not significantly
increased (P = 0.15) in the IgAN group compared with the other
groups. In an earlier study, increased binding to type IV
collagen was observed [201. A possible explanation for these
discrepant results is that we have used native human collagen
type IV, whereas the earlier study used denatured bovine
collagen type IV. Although collagen type IV is also a normal
constituent of human mesangial matrix [29, 301, the mesangial
deposits of IgA in IgAN biopsies occur at sites distinct from
collagen type IV-containing areas [31]. Furthermore, IgA dep-
osition along the glomerular capillary walls, which contain
substantial amounts of collagen type IV [29], is not common in
IgAN. Taken together, these findings suggest that collagen type
IV is not a target for the binding of IgA in the mesangial matrix.
The molecular mechanism of the increased binding of IgA to
the various ECM preparations is uncertain. Theoretically, both
an autoantibody type of interaction as well as interactions
unrelated to the antigenic specificity might be involved. An
important example of the latter is the interaction between
collagens and fibronectin complexed to the circulating IgA, first
reported by Cederhoim, Bygren and Heinegard [21]. In absorp-
tion experiments we attempted to differentiate between these
possible mechanisms, and to elucidate the role of IgA-fibronec-
tin aggregates. The finding that preabsorption to gelatin-coated
beads markedly reduced the binding to collagen types Ito IV is
compatible with fibronectin-mediated binding: gelatin (dena-
tured collagen type I) contains the fibronectin-binding domain
of collagen type I and thus may remove IgA-fibronectin aggre-
gates from the sample. The denaturation of collagen type I in
the conversion to gelatin destroys the triple helical structure
characteristic of collagens, and consequently removes the
epitopes against which autoantibodies to native collagen types
are directed. Consequently, absorption to gelatin should not
affect the titer of true autoantibodies directed at determinants in
the native collagen molecule. In the present study, little effect
of gelatin absorption was found on the binding of IgA to
collagen types V and VI. Similarly, the fluid-phase inhibition
experiments showed that collagen type I markedly inhibited the
binding of IgA to collagen types I to IV, but had much less
effect on types V and VI. These findings suggest that the
interaction of serum IgA with the latter types of collagen is not
mediated through fibronectin, but rather represents true auto-
antibodies. To our knowledge, no study has analyzed the
relative binding capacities for fibronectin in the various collagen
types.
The similarity between the IgAN and HIV groups in their
increased binding of IgA to the collagen types II and III raises
the question of whether fibronectin-mediated binding plays any
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role in the binding of IgA to the mesangium in IgAN [211. Based
on our data, mesangial deposition of IgA should also occur in
HIV-infected patients, if this mechanism is pathogenetically
relevant. Alternatively, if binding of IgA to collagen type V is
indeed responsible for the mesangial targeting in IgAN, IgA
deposits should also be found at other sites in the body with a
substantial content of this type of collagen. In this regard, the
somewhat controversial finding of vascular IgA deposits in skin
and skeletal muscle in IgAN is of interest [32—34]. Collagen type
V is an important constituent of the pericellular matrix of
vascular smooth muscle cells [29]. Despite the results in bur
study pointing to a possible role for IgA anti-collagen type V
autoantibodies, doubt remains concerning their pathogenetic
role. First, we were unable to demonstrate consistent binding to
the mesangium using immunofluorescence with the selected
sera. Secondly, although the profound differences found be-
tween the races make comparisons questionable, a very high
level of IgA binding to collagen type V and to the kidney extract
was also found in the Black HIV patients (Table 1). If such
binding is pathogenetically relevant, one would have to make
the improbable assumption that these Black HIV patients had
clinically unnoticed mesangial deposits of IgA.
For the IgG and 1gM isotypes few differences were observed
in the levels of binding to the various ECM preparations
between the three study groups. The degree of statistical
significance was considerably lower than for the differences in
the IgA isotype, precluding any firm conclusions. Remarkably,
in each of the three instances where significant differences were
found, one of the patient groups displayed lower values of
binding to the ECM preparation than the healthy control group.
Thus, the relevance of this decreased binding, if any, is specu-
lative. One possible explanation is that increased levels of
ECM-binding IgA in the patient sera competitively inhibited the
binding of other isotypes to the same ligand.
The results of our study with respect to the HIV patients may
be at variance with a recent report [35]. In that study, increased
binding of IgG to gelatin was reported in HIV-positive individ-
uals and HIV-negative homosexuals. However, an important
distinction between the two studies is that we used native
collagen preparations, whereas gelatin (denatured collagen type
I) was used in the other study. It remains uncertain whether
autoantibodies to collagen were measured in that study; per-
haps more likely it was a fibronectin-mediated interaction
between IgG and gelatin. In support of the latter explanation,
fibronectin was a potent inhibitor of the binding of IgG to the
gelatin [35].
The effects of age, gender, and race observed in our results
were unexpected, and have not yet been investigated further. A
study of these effects clearly should entail a more balanced
group composition with regard to gender and race. However,
the finding of the effects of age, gender, and race underlines the
need to take these factors into consideration in comparable
studies in the future.
In summary, we report increased binding of serum IgA to
various components of the ECM in patients with IgAN. The
mechanism of this increased binding appears in part to be
mediated through fibronectin, especially for the non-mesangial
collagen types I to III. However, similarly increased IgA
binding to these collagen types was also found in sera from
patients with HIV infection, a condition not associated with
mesangial deposition of IgA. More characteristic for IgAN was
increased IgA-biñding to collagen type V (common in mesangial
matrix), which was not found in White patients with HIV
infection. The interaction between IgA and collagen type V in
IgAN may be independent of fibronectin, and perhaps the result
of autoantibody formation. However, the pathogenetic role of
IgA-collagen interactions in IgAN remains to be elucidated.
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